单次术前氨甲环酸减少围术期失血:一项Meta分析
该Meta分析检索截至2018年11月的随机对照试验,评估单次术前静脉氨甲环酸(TXA)的疗效与安全性。共纳入57项研究、5698例手术患者,结果显示TXA组围术期估计失血量更低,输血 odds 降低72%,静脉血栓栓塞事件发生率与对照组无差异。
要点
- 单次术前静脉TXA可降低围术期失血量,标准均数差为-153.33 mL(95%CI -187.79至-118.87)。
- TXA组输血 odds 降低72%(OR=0.28,95%CI 0.22-0.36)。
- TXA组与对照组静脉血栓栓塞事件发生率无差异。
核心结论
- 单次术前静脉TXA可减少多种手术学科的围术期失血和输血需求,且不增加血栓栓塞事件风险。
研究设计与样本
- 检索Medline、Cochrane Central和Embase至2018年11月,纳入成人随机对照试验,由两名独立评价者及仲裁者评估纳入。
- 共筛选1906篇文章,57篇符合纳入标准;总样本量5698例。
主要发现
- 纳入研究以骨科最多(27项),其次为产科和妇科(16项)、口腔颌面及耳鼻喉科(10项)、心脏外科(3项)和整形外科(1项,聚焦急性烧伤重建)。
- 所有外科专业合计(n=5698),TXA组围术期估计失血量更低,标准均数差为-153.33 mL(95%CI -187.79至-118.87)。
- TXA组手术患者输血 odds 降低72%(OR=0.28,95%CI 0.22-0.36)。
- 最常用的TXA剂量为15 mg/kg。
- TXA组与对照组静脉血栓栓塞事件发生率无差异。
关键数值与推荐
- 纳入标准:单次术前静脉推注TXA、手术患者、测量术中失血量或术后24小时内围术期失血量。
- 主要结局为手术失血量;次要结局包括静脉血栓栓塞并发症、输血需求和剂量。
临床怎么用
- 可考虑将单次术前静脉TXA用于预防性减少手术出血,尤其适用于择期日间手术的拓展应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review the efficacy and safety of a single dose of intravenous tranexamic acid (TXA) given preoperatively. SUMMARY BACKGROUND DATA: TXA is a synthetic antifibrinolytic that has been used in various surgical disciplines to reduce blood loss, blood transfusions, ecchymosis, and hematoma formation. However, there is no universal standard on the most effective dose and route of TXA administration, limiting its routine use in many centers. This study evaluates the current evidence for the efficacy and safety of a single preoperative dose of TXA on surgical blood loss in all surgical disciplines. METHODS: With the guidance of a research librarian, in accordance with the Cochrane Handbook Medline, Cochrane Central and Embase were searched in November 2018. Search terms included "Tranexamic Acid" AND "Intravenous," with studies limited to randomized controlled trails in adult humans. Two independent reviewers and an arbitrator assessed articles for inclusion. Criteria included a single preoperative bolus dose of intravenous TXA, surgical patients, and intraoperative blood loss measurement or perioperative blood loss up to 24 hours postsurgery. Quality assessment was done using the Cochrane Collaboration risk-of-bias tool by 2 reviewers. Statistical analysis was carried out using Cochrane Review Manager 5.3. The primary outcome was surgical blood loss. Secondary outcomes included venous thromboembolic complications, transfusion requirements, and dosing. RESULTS: A total of 1906 articles were screened, 57 met inclusion criteria. The majority of included studies were orthopedic (27), followed by obstetric and gynecological (16), oral maxillofacial and otolaryngology (10), cardiac (3), and 1 plastic surgery study focusing on acute burn reconstruction. Across all surgical specialties (n = 5698), the perioperative estimated blood loss was lower in patients receiving TXA, with a standard mean difference of -153.33 mL (95% CI = -187.79 to -118.87). Overall, surgical patients with TXA had a 72% reduced odds of transfusion (odds ratio = 0.28 [95% CI = 0.22-0.36]). The most frequently used dose of TXA was 15 mg/kg. There was no difference in the incidence of venous thromboembolic events between TXA and control groups. CONCLUSIONS: While there is a growing body of evidence to support benefits of perioperative TXA use, this is the first meta-analysis to identify the efficacy and safety of a single preoperative dose of IV TXA. The potential implications for expanding the use of preoperative TXA for elective day surgery procedures is substantial. Preoperative intravenous TXA reduced perioperative blood loss and transfusion requirements in a variety of surgical disciplines without increasing the risk of thromboembolic events. Therefore, it should be considered for prophylactic use in surgery to reduce operative bleeding.
引用
- Heyns M, Knight P, Steve AK, et al. A Single Preoperative Dose of Tranexamic Acid Reduces Perioperative Blood Loss: A Meta-analysis. Ann Surg. 2021. PMID: 32224739. doi:10.1097/SLA.0000000000003793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。